During 2018 Q4 the big money sentiment decreased to 0.9. That’s change of 0.31, from 2018Q3’s 1.21. 35 investors sold all, 44 reduced holdings as PTLA ratio is negative. 50 grew positions while 21 funds amassed positions. Funds hold 63.72 million shares thus 3.36% less from 2018Q3’s 65.93 million shares. Rothschild Inv Il reported 17,010 shs. Moreover, Northern Corp has 0% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 803,879 shs. Price T Rowe Associates Md holds 74,979 shs or 0% of its capital. Profund Advsrs Limited Liability Company reported 19,687 shs stake. Deutsche Savings Bank Ag stated it has 0% of its capital in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Sphera Funds Mgmt Ltd owns 147,000 shs. Adage Group Limited Liability Company reported 475,000 shs. Ameriprise Financial Inc has 0% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Jefferies Gp Limited Liability Corp reported 233,600 shs stake. Creative Planning holds 0.02% or 302,900 shs in its capital. Pictet Asset Mgmt Limited has 66,542 shs for 0% of their capital. Franklin Resource holds 1.07 million shs. Victory Capital Mngmt has 1,539 shs for 0% of their capital. Jackson Square Prtnrs Ltd Liability holds 1.94 million shs. Oppenheimer & Com Inc holds 0.02% of its capital in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 24,756 shs.

PTLA had 1 insider sale and 0 buys since December 17, 2018. This’s net activity of $1.20 million.

According to 2018Q4 Securities and Exchange form the Highland Capital Management Lp increased its holdings in Portola Pharmaceuticals Inc (PTLA) by 34.7%. The company’s stock rose 59.12% with the market as Highland Capital Management Lp bought 407,574 shares. At the end of 2018Q4, the 1.58 million shares of the health care company held by the hedge fund were priced at $30.88M, up from 1.17M at the end of the previous reported quarter. $2.32B is the market cap of Portola Pharmaceuticals Inc. PTLA is hitting $34.7 during the last trading session, after increased 3.30%.Currently Portola Pharmaceuticals, Inc. is uptrending after 5.58% change in last March 31, 2018. PTLA has 1.09M shares volume. PTLA outperformed the S&P500 by 1.21%.

Highland Capital Management Lp operates about $15.04B and $1.30B US Long portfolio. It reduced its stake in Teledyne Technologies Inc (NYSE:TDY) by 38,000 shares to 1,400 shares, valued at $290,000 in 2018Q4, according to the filing. Highland Capital Management Lp has cut its stake in Bio Rad Labs Inc (NYSE:BIO) and also reduced its holding in Visa Inc (NYSE:V) by 81,584 shares in the quarter, for a total of 75,000 shares.

For more Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news brought out recently go to: Fool.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Why Portola Pharmaceuticals Skyrocketed 15.3% Today – The Motley Fool” brought out on March 01, 2019, “Portola Pharmaceuticals to Webcast Presentation at Cowen and Company’s 39th Annual Health Care Conference – Nasdaq” on March 06, 2019, “XBI, ONCE, PBYI, PTLA: Large Inflows Detected at ETF – Nasdaq” with a publish date: March 19, 2019, “Notable Friday Option Activity: ROKU, SHEN, PTLA – Nasdaq” and the last “Can You Win With Portola Pharmaceutical Options? – Seeking Alpha” with publication date: March 25, 2019.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

In total 4 analysts cover Portola Pharmaceuticals (NASDAQ:PTLA). “Buy” rating has 3, “Sell” are 0, while 1 are “Hold”. (NASDAQ:PTLA) has 75% bullish analysts. 6 are the (NASDAQ:PTLA)’s ratings reports on 31 Mar 2019 according to StockzIntelligence Inc. On Thursday, November 8 the stock has “Neutral” rating by Credit Suisse. On Thursday, October 11 the firm has “Equal-Weight” rating given by Morgan Stanley. On Monday, March 4 the stock has “Buy” rating by Oppenheimer. On Monday, March 4 the rating was maintained by Credit Suisse with “Hold”. On Monday, March 4 the stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Buy” rating given by Morgan Stanley. On Monday, March 4 the stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Buy” rating by Citigroup.